Use the Back button in your browser to continue reading the
article.
References: (1) Carr A, Miller J, Law M,
Cooper DA (2000). A syndrome of lipoatrophy, lactic acidaemia and liver
dysfunction associated with HIV nucleoside analogue therapy: contribution
to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25-32.
(2) Carr A, Cooper DA (1998). Lipodystrophy associated
with an HIV-protease inhibitor. N Engl J Med 339:1296.
(3) Miller KD, Jones E, Yanovski JA, Shankar R,
Feuerstein I, Fallon J (1998). Visceral abdominal-fat accumulation
associated with use of Indinavir. Lancet 351:871-875.
(4) Kingsley L, Smir E, Riddler S, Li R, Chmiel J, F. P,
Vissscher B, Oishi J, Taylor E, Dobs A, Evans R (2001) Prevalence of
lipodystrophy and metabolic abnormalities in the multicenter AIDS cohort
study (MACS). 8th Conference on Retroviruses and Opportunistic Infections,
Chicago.
(5) Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M
(1998). Buffalo Hump in Men with HIV-I infection. Lancet 351:867-70.
(6) Hadigan C, Meigs JB, Corcoran C, Rietschel PR,
Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PWF, D'Agostino RB,
Grinspoon S (2001). Metabolic abnormalities and cardiovascular disease
risk factors in adults with Human Immunodeficiency Virus infection and
lipodystrophy. Clin Inf Dis 32:130-9.
(7) Kotler DP, Rosenbaum KB, Wang J, Pierson RN (1999).
Studies of body composition and fat distribution in HIV-infected and
control subjects. J Acq Imm Def Syndr and Hum Retr 20:228-37.
(8) Hadigan C, Corcoran C, Stanley T, Piecuch S,
Klibanski A, Grinspoon S (2000) Fasting hyperinsulinemia in HIV-infected
men: relationship to body composition, gonadal function and
protease-inhibitor use. J Clin Endocrinol Metab 85:35-41.
(9) Carr A, K. S, Chisholm DJ, Cooper DA (1998).
Pathogenesis of HIV-1-protease-inhibitor-associated peripheral
lipodystrophy, hyperlipidemia and insulin resistance. Lancet
352:1881-3.
(10) Lichtenstein K, Ward D, Delaney K, Moorman A,
Palella F, Young B, Wood K, Holmberg S (1999). Clinical factors related to
the severity of fat redistribution in the HIV outpatient study (HOPS). 1st
International Workshop on Adverse Drug Reactions and Lipodystrophy, San
Diego.
(11) Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J,
Gelato MC (2000). Association of severe insulin resistance with both loss
of limb fat and tumor necrosis factor receptor levels in HIV
lipodystrophy. J Acquir Immune Defic Syndr 25:312-21.
(12) Grunfeld C, Pang M, Doerrler W (1991). Circulating
interferon alpha levels and hypertriglyceridemia in the Acquired
Immunodeficiency Syndrome. Am J Med 90:154-62.
(13) Grunfeld C, Pang M, Doerrler W, Shigenaga JK,
Jensen P, Feingold KR (1992). Lipids, lipoproteins, triglyceride
clearance, and cytokines in human immunodeficiency virus infection and the
acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045-52.
(14) Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari
R, Leonard JM, Locke C, Brunzell JD (2000). Effect of ritonavir on lipids
and post-heparin lipase activities in normal subjects. AIDS 14:51-7.
(15) Carr A, Samaras K, Burton S, Law M, Freund j,
Chisolm DJ, Cooper DA (1998). A syndrome of peripheral lipodystrophy,
hyperlipidemia and insulin resistance in patients receiving protease
inhibitor therapy. AIDS 12:F51-F58.
(16) Murata H, Hruz PW, Mueckler M (2000). The mechanism
of insulin resistance caused by HIV protease inhibitor therapy. J Biol
Chem 275:20251-4.
(17) Noor MA, Lo JC, Mulligan K, Schwartz J, Halvorsen
RA, Schambelan M, Grunfeld C (2001). Metabolic effects of Indinavir in
healthy HIV-seronegative men. AIDS 15:F11-8.
(18) Hadigan C MJ, Rabe J, D'Agostino RB, WIlson PWF,
Lipinska I, Tofler GH, Grinspoon S (2000). Increased tPA antigen levels
are reduced with metformin therapy in HIV-infected patients with fat
redistribution and insulin resistance. J Clin Endocrinol Metab 86:939-43.
(19) Depairon M, Chessex S, Sudre P, Rodondi N, Doser N,
Chave J, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V (2001).
Premature atherosclerosis in HIV-infected individuals - focus on protease
inhibitor therapy. AIDS 15:329-34.
(20) Mary-Krause M, Cotte L, Partisani M, Simon A,
Costagliola D (2001). Impact of treatment with protease inhibitor (PI) on
myocardial infarction (MI) occurrence in HIV-infected men. 8th Conference
on retroviruses and Opportunistic Infections, Chicago.
(21) Klein D, Hurley L, Sorrel M, Sidney S (2001). Do
protease inhibitors increase the risk for coronary heart disease among HIV
positive patients? Follow up through June 2000. 8th Conference on
Retroviruses and Opportunistic Infections, Chicago.
(22) Martinez E, Conget I, Lozano L, Casamitjana R,
Gatell JM (1999). Reversion of metabolic abnormalities after switching
from HIV-1 protease inhibitors to nevirapine. AIDS 13:805-10.
(23) Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P,
Grinspoon S (2000). Metformin in the Treatment of HIV Lipodystrophy. JAMA
284:472-7.
(24) Arioglu E, Duncan-Morin J, Sebring N, Rother KI,
Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A,
Sumner AE, Hoofnagle J, Reitman ML, Taylor SI (2000). Efficacy and safety
of troglitazone in the treatment of lipodystrophy. Ann of Int Med
133:263-74.
(25) Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht
M (1999). Recombinant human growth hormone improves the fat redistribution
syndrome (lipodystrophy) in patients with HIV. AIDS
13:2099-103.
|